Connect with us

Technology

Selvita reports Q1 2026 results and launches strategic options review

Published

on

KRAKÓW, Poland, May 21, 2026 /PRNewswire/ — Selvita S.A. (WSE: SLV), one of the leading Drug Discovery and Development organizations in Europe, has published its financial results for Q1 2026 and latest backlog. The Company has decided to launch a strategic options review for the Group’s further development and to maximize long-term shareholder value.

The Group’s operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin(1) reached 14%, compared to the estimated range of 13-16%. As a result of the cost-saving program implemented in H2 2025, operating costs in Q1 2026 were reduced by approximately EUR 1.5 million.Drug Development segment: Commercial revenues increased by 6% y/y in Q1 2026 to EUR 6.2 million, representing 35% of the Group’s commercial revenues. Segment EBITDA amounted to EUR 1.7 million, up 2% y/y(1). Segment backlog increased 15% y/y supporting the Group’s expectation of continued future growth driven by strategic alignment to fast-growing modalities.Drug Discovery segment: Commercial revenues in Q1 2026 amounted to EUR 11.6 million, compared to EUR 15.6 million in the prior year. Segment EBITDA(1) amounted to EUR 1.0 million, compared to EUR 1.9 million in Q1 2025.  This was primarily due to the continuing challenging market for outsourced European drug discovery services companies and some project delays.The full-year 2026 backlog as of May 18, 2026 stands at EUR 58.1 million(2) compared to EUR 58.9 million last year.A webcast to discuss Selvita’s Q1 results and outlook for 2026 will be held on May 21 at 11:00 CET. The event will be available at live.selvita.comSelvita announced the launch of a strategic review to assess options to support the Group’s further development and maximize shareholder value.

Boguslaw Sieczkowski, Co-Founder, significant shareholder and Chief Executive Officer of Selvita said:

“We are observing a progressive recovery in the biotechnology sector, particularly in the United States. However, the market remains volatile, as reflected, amongst other factors, in our Q1 results. We are focusing our efforts on ensuring that the subsequent periods show clear improvement, reflecting the acceleration of growth in Drug Development and a stabilized performance in Drug Discovery. Our profitability is supported by the cost-saving program implemented in the second half of 2025.

“The Drug Development segment has grown by 20-25% in recent years and is now a key growth driver for the Group, already accounting for more than one-third of commercial revenues. We see potential for its further development and have identified specific pathways by which we can accelerate growth in this segment.

“The Drug Discovery segment continues its transformation, driven by ongoing structural changes in the outsourced European drug discovery services market. Last year, we optimized the segment’s resources. We are currently focusing our efforts on more complex, high-margin services and increasing automation.”

Dariusz Kurdas, Management Board Member and Chief Financial Officer of Selvita, said:

“With EUR 19.1 million in operating revenues and a 14% EBITDA margin, we came in the middle of the range of the Q1 preliminary estimates published earlier. In the Drug Discovery segment we observed some project delays. These projects are still expected in the remaining quarters of the year, supporting improved financial performance compared to Q1. This year, we expect an improvement in profitability thanks to the approximately EUR 6.4 million in savings under the optimization program.”

STRATEGIC OPTIONS REVIEW

Selvita has continued to observe contrasting market dynamics across Drug Discovery and Drug Development.

In Drug Discovery, the European outsourced services market has remained challenging. However, the Group sees encouraging signs in the biotechnology funding environment and preliminary signs of increased levels of new pipeline opportunities which will support improved performance for the remainder of 2026 compared to Q1. Over the medium term, the Group expects continued headwinds in certain areas of small molecule Drug Discovery, whilst demand for high value-add and integrated services, especially for advanced modalities, is expected to continue to grow.

In Drug Development, the Group expects to see continued momentum in demand for services, notably in fast-growing advanced modalities.

In light of this market backdrop, Selvita has commenced a broad strategic review to assess options which would support the Group in achieving larger scale and maximizing long-term shareholder value.

The Group is considering, and is open to, a variety of strategic options, which may include a take private transaction, or an acceleration of Selvita’s M&A and organic growth initiative capital deployment strategy. This includes scenarios where additional financing would be considered solely to support such value-accretive opportunities and incremental growth initiatives.

Selvita has not set a timetable for the review, nor has it made any decisions at this stage regarding the selection of or preference for any option. Updates on the conclusion of the strategic review will be publicly communicated by Selvita as and when appropriate, and in accordance with applicable regulations.

The strategic options review will be conducted with a strong focus on uninterrupted client service, operational stability, and continued excellence in project delivery.

To facilitate the strategic review, Selvita has engaged Rothschild & Co as financial adviser.

Boguslaw Sieczkowski said:

“It is our belief that the Drug Discovery and Drug Development markets are evolving to favour players of larger scale with broad geographic and service offering capabilities across modalities. We do not believe the Group’s current valuation reflects its growth trajectory in Drug Development and unique capabilities and market positioning in Drug Discovery. We, therefore, think that now is an appropriate time to assess our potential strategic options. The underlying premise of the process is to improve the prospects of each of the Group’s segments and deliver shareholder value.”

Q1 2026 FINANCIAL RESULTS

Operating revenues in Q1 2026 amounted to EUR 19.1 million, compared to EUR 21.8 million in the prior year. The negative impact of foreign exchange differences on revenues amounted to approximately EUR 0.2 million.

Group EBITDA in Q1 2026 amounted to EUR 2.7 million, compared to EUR 3.6 million in the prior year(1). The EBITDA margin reached 14%. Savings resulting from the implemented optimization program amounted to approximately EUR 1.5 million.

Commercial revenues in the Drug Discovery segment in Q1 2026 amounted to EUR 11.6 million, compared to EUR 15.6 million in the prior year. Segment EBITDA(1) amounted to EUR 1.0 million, compared to EUR 1.9 million in the prior year.

Commercial revenues in the Drug Development segment in Q1 2026 amounted to EUR 6.2 million, up 6% y/y, already accounting for 35% of total commercial revenues. Segment EBITDA reached EUR 1.7 million, up 2% y/y, corresponding to a margin of 27%(1).

BACKLOG FOR 2026(2)

The Group’s backlog for 2026 amounts to EUR 58.1 million compared to EUR 58.9 million in the same period last year.

The backlog in the Drug Discovery segment stands at EUR 35.3 million (down 13% y/y), while in the Drug Development segment it amounts to EUR 19.4 million (up 15% y/y).

DRUG DISCOVERY TECHNOLOGIES DEVELOPMENT PROGRAM FOR 2026-2029

In recent quarters, Selvita secured four non-dilutive grants with a combined subsidy value of EUR 26.4 million. Nearly half of this amount – EUR 12.0 million – will be invested in the development of advanced services in 2026-2029. Together, these projects represent the most intensive technology development program in the Group’s history, spanning most departments within the Drug Discovery segment and incorporating a significant AI component.

The remaining portion of the grant funding will support infrastructure development, including the acquisition of state-of-the-art equipment and, in 2028-2029, the expansion of Selvita’s own laboratory space in Kraków. The potential investment in new, specialized research facilities will be financed through a combination of grant funding (approx. 40%), bank debt (approx. 50%), and the Group’s own funds (approx. 10%). In March 2026, Selvita signed a loan agreement securing financing for the investment. The largest share of capital expenditures is planned for the final phase of the investment, scheduled for 2029.

     (1) Results exclude non-cash costs of the non-dilutive employee incentive program.
     (2) Backlog as of May 18, 2026 and May 19, 2025; includes the revenues already invoiced in the financial year and portfolio of orders for the financial year.

All % calculated from PLN. All values are calculated from PLN using an average exchange rate for the respective reporting period.

About Selvita (WSE: SLV; sWIG80)

Selvita is one of the leading Drug Discovery and Development organizations in Europe. The Company provides comprehensive solutions supporting clients and their programs across a broad range of therapeutic areas, with expertise in infectious diseases, inflammation, fibrosis, and oncology. Selvita offers a wide range of standalone and fully integrated drug discovery and development solutions. Its service portfolio spans the entire value chain, from early-stage drug discovery to preclinical development, for both small molecules and therapeutic antibodies.

The Selvita Group has been operating since 2007 and employs approximately 900 highly qualified specialists. More than 30% of Selvita’s scientists hold a PhD degree. The Group’s headquarters and main laboratories are located in Kraków, Poland, with additional research facilities in Poznań, Wrocław, and Zagreb, Croatia. The Company’s sales offices are located in major global biotech hubs, including the Boston and San Francisco Bay Areas in the United States, as well as Cambridge in the United Kingdom.

Selvita is listed on the Warsaw Stock Exchange (WSE: SLV) and is a component of the sWIG80 index.

For more information, please visit: www.selvita.com

 

View original content:https://www.prnewswire.com/news-releases/selvita-reports-q1-2026-results-and-launches-strategic-options-review-302778547.html

SOURCE Selvita S.A.

Continue Reading

Technology

Poll finds surging demand for AI-based video encoding

Published

on

By

HANGZHOU, China, Sept. 21, 2026 /PRNewswire/ — Hikvision has developed Guanlan Encoding, a technology that uses AI to identify more and less information-rich areas in video images and encodes every frame accordingly.

To gauge the potential impact of the new technology, asmag.com and Hikvision have teamed up for a survey of asmag readers, entitled “AI encoding technology for video security,” and asked them about their experience with the “storage challenge” and where they see potential in their projects for AI-based encoding.

Storage pressure is real and growing

When asked “How significant a challenge is video storage cost or capacity in your business or projects?” a large number of respondents—38.2%—identified storage pressure as a “major challenge.” It was the second-most given answer among all respondents, trailing closely behind 43.2% who said storage is a “moderate” challenge. When asked “Has the storage challenge changed compared to 12 months ago?” the largest share of respondents—once again 43.2%—said it has “increased moderately.” 

Guanlan Encoding—Hikvision’s solution to a growing pain point

Guanlan Encoding is built on the H.265 standard and integrates Hikvision’s Guanlan Large-Scale AI Model into continuous encoding workflows. Rather than compressing every part of a frame equally—the approach traditional codecs take—Guanlan Encoding identifies which parts of a scene matter most, such as people, vehicles and other moving objects, and allocates more detail to them. Static or low-motion background footage, by contrast, is compressed far more aggressively.

According to Hikvision, this combination of different compression rates in the same frame helps reduce storage needs by 30% to 50% on average without sacrificing details that matter for investigations and monitoring.

Guanlan is already gaining ground

Even though it was introduced so recently, over half of survey respondents expressed familiarity with Guanlan Encoding: 43.3% said they are “familiar with it” despite not yet having hands-on experience, while 8.3% said they are already using the technology.

Overall, the survey showed the severity of the storage challenge, but also that Hikvision is well positioned to offer a significant fix to the pain point. Guanlan Encoding plays a key role as it uses AI not to produce more data, but to reduce the burden of more data on storage infrastructure.

Find more reporting about the “AI encoding technology for video security” on the dedicated landing page on asmag.com, or download the full results of the survey.

View original content to download multimedia:https://www.prnewswire.com/news-releases/poll-finds-surging-demand-for-ai-based-video-encoding-302885423.html

SOURCE Hikvision Digital Technology

Continue Reading

Technology

Noah Holdings Hosts 2026 Global Investor Summit “The Year of Realization: A New Chapter in Global Allocation”

Published

on

By

Serving Global Chinese Families With a Global Investment Network, Licensed Teams and AI Capabilities

HONG KONG, Sept. 21, 2026 /PRNewswire/ — Noah Holdings Limited (“Noah” or the “Company”) (NYSE: NOAH; HKEX: 6686), a wealth management institution serving global Chinese families, together with its global asset allocation platform Olive Asset Management (“Olive”), successfully held its 2026 Global Investor Summit, themed “The Year of Realization: A New Chapter in Global Allocation,” in Hong Kong. Addressing the industry transformation driven by AI and the long-term wealth needs of global Chinese families, Noah discussed how it is combining the global investment network and professional expertise it has developed over the years with AI capabilities to build a wealth management system that clients can use and rely on over the long term.

Investment professionals from Global Infrastructure Partners (GIP, a part of BlackRock), Macquarie Asset Management, Bridgepoint, HarbourVest Partners and Sumitomo Mitsui Trust Asset Management attended the summit and participated in discussions. Noah’s global network of investment managers is an important foundation of its investment capabilities. Through its ongoing investments in funds globally, Noah and Olive continue to build relationships with managers and accumulate underlying research data, drawing on these resources to understand industry shifts, validate investment judgments and support clients’ long-term asset allocation.

Understanding the Responsibility of Wealth Management, Starting From Clients’ Long-Term Interests

Noah Holdings believes that the productivity shift brought by AI is changing how wealth is created and is placing new demands on families’ long-term planning. Wealth management needs to understand the long-term forces behind changes in technology, capital and family needs, while also factoring in family governance and succession. The responsibility of professional institutions is to help clients understand these changes and make judgments based on their own needs, building trust through long-term engagement.

Noah Holdings Chairwoman Norah Wang said: “Care is what expertise is for – that has always been Noah’s foundation. Our job is not to predict events, but to identify forces. Real care means using professional judgment to help clients see clearly which fluctuations they can bear, and which risks they must avoid.”

Noah Holdings CEO Zander Yin said at the summit that every technological revolution rewrites the world order and redraws the map of resources. The productivity shift now being driven by AI is no exception – it is likewise changing the path for corporate growth and investor participation.

Yin said: “The industrial revolutions of the past freed human hands; this AI revolution is further extending the human brain and human intelligence. Noah’s long-accumulated insight into GPs lets us keep observing how leading investment institutions make their choices. With AI, we are connecting this accumulated knowledge into clearer research threads – this ‘map’ is the trajectory of choices made by the world’s leading institutions. Following this map to identify companies worth deeper research is the approach we take.”

These judgments ultimately need to be embedded in a system clients can use. Noah’s three platforms operate in coordination: ARK Wealth Management handles account services and investment execution, covering the global banking system, trading channels, mutual funds and structured products; Olive Asset Management is responsible for long-term asset allocation, covering private equity, venture capital, real estate and global infrastructure; and Glory Family Heritage focuses on family protection and intergenerational planning, providing global family succession and lifestyle services. The three platforms work together within a unified framework to translate clients’ long-term needs into concrete investment, allocation and succession arrangements.

Noah Olive’s “Institutional Intelligence”: Making Judgment Evidence-Based and Experience Cumulative

Olive Asset Management Global CEO Peng Jing said at the summit that Olive is continuing to build its “institutional intelligence,” turning the research, decisions and experience accumulated through long-term investment practice into shared organizational methods and standards, so that professional judgment can accumulate over time, be tested, and improve through practice.

Observing the choices made by top-tier institutions is the starting point for research, not the conclusion. A global network of managers provides breadth of research, but institutional prestige and the number of investments alone cannot substitute for judgment. The team tracks how many genuinely independent sources of information support a given judgment, rather than simply counting how many firms have co-invested. At the execution level, Olive evaluates company quality and purchase price separately; at the research level, screening models need to be tested using only the information available at each historical point in time, with the methodology then refined based on actual outcomes. Project data, the basis for decisions, and the lessons drawn from both successes and mistakes are thereby retained within the organization over time. In this process, AI helps expand information coverage, detect anomalies and maintain ongoing tracking, while the professional team remains responsible for industry judgment, risk assessment and final decisions.

The summit also included a series of breakout sessions on topics such as cutting-edge technology in Silicon Valley, positioning in global private markets, opportunities in public markets, and family succession planning, with professionals from Noah and partner institutions taking part in the discussions.

Noah will continue to connect global investment resources, professional research and client service, working through its platforms to support the long-term investment and wealth succession needs of global Chinese families.

About Noah Holdings Limited

Noah Holdings Limited (NYSE: NOAH; HKEX: 6686) is a Singapore-headquartered wealth management institution focused on serving global Chinese high-net-worth families. Founded in 2005, Noah listed on the New York Stock Exchange in 2010 and completed a dual primary listing on the Hong Kong Stock Exchange in 2022. The Company’s business spans nine countries and regions, with account and trading centers in Singapore, Hong Kong, China, the United States, and Shanghai, China.

Disclaimer:

This press release is for reference only and does not constitute investment advice, an offer, or a solicitation of an offer to invest. Investing involves risk; the prices of securities and funds can rise as well as fall, and past performance is not indicative of future performance. The forward-looking statements contained in this release are subject to a variety of risks and uncertainties, and actual results may differ materially from these statements.

View original content:https://www.prnewswire.com/news-releases/noah-holdings-hosts-2026-global-investor-summit-the-year-of-realization-a-new-chapter-in-global-allocation-302885425.html

SOURCE Noah Holdings Limited

Continue Reading

Technology

When Music Reads Emotion: THEi Launches Centre for Music Therapy Research to Deepen Guangdong-Hong Kong Integration and Leverage AI to Fill the Healthcare Talent Gap

Published

on

By

Download high-res photo here: https://bit.ly/4rcZWOx 

HONG KONG, Sept. 22, 2026 /PRNewswire/ — The fast pace of modern life and an aging population drive demand for mental health and non-pharmacological holistic wellness. In alignment with the health development priorities of the national 15th Five-Year Plan and the Healthy China Initiative, the Technological and Higher Education Institute of Hong Kong (THEi) held the launch ceremony for its Centre for Music Therapy Research (CMTR) at the Sky Concert Hall in Shenzhen on 16 September. The launch aims to address the demand for innovative healthcare talent while fostering Guangdong-Hong Kong integration.

The event gathered prominent leaders across government, business, higher education, and technology sectors, including Mr Paul CHONG Kin-lit, BBS, MH, Vice Chairman, THEi’s Board of Governors; Professor Alan LAU Kin-tak, President of THEi; Ms LIU Ying,

Adjunct Associate Professor, Department of Digital Innovation and Technology, THEi and

Director of Centre for Music Therapy Research, THEi; Mr YANG Pengda, Education Entrepreneur and Deputy Director of Centre for Music Therapy Research, THEi;  Mr WAN Kun, Deputy Director-General, Development and Reform Bureau of Futian District, Shenzhen Municipality; Ms MA Hui, Director of Tchaikovsky Conservatory (China) International Exchange Centre; Dr CAI Yuejun, Key Laboratory of AI-Enabled Music Therapy, Shanghai Conservatory of Music; Dr PANG Yan, Associate Research Professor, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS); Doctoral Supervisor, University of Chinese Academy of Sciences (UCAS).

The event featured strategic partnership signing ceremonies and a cross-industry networking reception, alongside an immersive “Emotional Healing Show” concert performed by celebrated musicians, including winners of ‘Golden Bell Awards’ and ‘Wenhua Award’, as well as former members of the renowned Twelve Girls Band. A key highlight was the live instrumental and choral performance of the iconic pop song Beneath the Lion Rock, which resonated with the Centre’s positioning of “Hong Kong’s International Connectivity”—marking a major milestone of advancing interdisciplinary mind-body wellness in the GBA.

Empowering Big Health with Applied Sciences: Nurturing “Work-Ready” Professionals in the GBA

Mr Paul CHONG Kin-lit, BBS, MH, Vice Chairman, THEi’s Board of Governors, delivered opening remarks, stating: “As an applied discipline bridging art, science, and medicine, music therapy plays a pivotal role in tackling mental stress, broader wellness demands, and specialised healthcare needs. Guided by our education philosophy of ‘applied science and immediate application,’ THEi drives industry-academia-research integration. By extending the reach of our Centre to Shenzhen, we leverage the GBA’s innovative ecosystem and expanding demand to pair global music therapy standards with cutting-edge technology—building a premier hub for scientific research, practical application, and community service.”

Professor Alan LAU Kin-tak, President of THEi, emphasised in his keynote that higher education must stay attuned to modern trends and national developments: “Music is undergoing a redefinition where sound, emotion, and AI intersect. As a pioneer in applied science and work-ready education, THEi sees growing demand in the GBA for expertise in non-pharmacological therapies, mental wellness, and the silver economy. By launching the Centre in Shenzhen, we fuse academic research with regional innovation. Through short-term and professional training programmes, we aim to fast-track market-ready, multidisciplinary talent equipped with technological, clinical, and commercial expertise to directly address key social needs.

Top Academic Talent Joins Forces

The newly launched Music Therapy Research Centre is directed by Ms LIU Ying, Visiting Associate Professor in the Department of Digital Innovation and Technology at THEi. A distinguished expert in Chinese traditional music, Ms LIU leads the Centre’s core content strategy, backed by international innovation expertise from Dr PANG Yan, Associate Research Professor, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (CAS); Doctoral Supervisor, University of Chinese Academy of Sciences (UCAS) and his team.

As the champion of the Guzheng category at the 9th Chinese Music ‘Golden Bell Awards’, and the exclusive recipient of the gold, silver, and bronze awards in this category. Ms LIU noted that the Centre maximises synergy between Hong Kong and Shenzhen by pairing “Hong Kong’s global perspective with Shenzhen’s development speed” to construct a regional cross-disciplinary hub. Guided by the vision of “medical treatment in hospitals, healing in daily life,” the Centre uses Five-Tone theory and AI-based EEG technologies to deliver non-clinical wellness solutions. She stressed that with a clear focus on problem-solving over sheer size, the Centre will advance practical training programs, therapeutic products, and industry benchmarks through the integration of arts, science, and commercialisation.

Mr YANG Pengda, Education Entrepreneur and Deputy Director of Centre for Music Therapy Research, THEi, underscored his belief that “investing in education is a high-value commitment, not a cost,” – a vision driving his multi-year support for THEi’s research centres. Praising THEi’s work-ready degree’s programmes – which features a 100% internship placement and over 95% graduate employment, he noted that the Institute’s programmes are tailored to industry needs. He emphasised that the new Centre is grounded in societal demand, tackling issues like sleep disorders affecting 300 million individuals and elder care for 320 million seniors—effectively leveraging technology and humanity to improve the quality of lives.

The Centre signed strategic MoUs with Key Laboratory of AI-Enabled Music Therapy, Shanghai Conservatory of Music and Tchaikovsky Conservatory (China) International Exchange Centre The partnerships will foster deep collaboration across music arts research, professional talent training, and international exchange, laying a solid artistic foundation for the Centre’s ongoing development.

Moving ahead, the Centre will focus its efforts on four core strategic pillars: advancing AI-assisted music therapy research to improve personalised non-pharmacological treatments; exploring traditional Chinese music to unlock its therapeutic emotional benefits; delivering arts-based healing to support seniors and individuals with special needs; and integrating digital music with immersive technology to drive music therapy beyond traditional stages into a smart, holistic era of care.

Following the official launch of the Centre and its upcoming professional training programmes, THEi is set to reinforce its leadership in regional applied science education—accelerating sustainable innovation to support high-quality development across the GBA and nationwide.

About the Bachelor of Arts (Honours) in Music Technology

The programme places a strong emphasis on cross-cultural exchange, covering three major professional domains: game music design, contemporary music composition, and film scoring. By integrating artificial intelligence and augmented reality/virtual reality (AR/VR) technologies into practical learning, the programme equips students with professional mastery in audio engineering and sound design, enhancing their ability to combine artistic creativity with technological innovation.

About Technological and Higher Education Institute of Hong Kong (THEi) 

Founded in 2012, the Technological and Higher Education Institute of Hong Kong (THEi) is a member institute of the Vocational Training Council (VTC). THEi offers over 20 professional “Applied Science-Oriented” undergraduate and postgraduate degree programmes across seven academic areas: Product and Fashion Designs, Sports and International Events Management, Digital Construction and Building Services, Horticulture, Arboriculture and Landscape Management, Chinese Medicine and Food Science, Hotel Management and Culinary Arts and Technology, and Digital Technology and Innovative Business. The programmes integrate theoretical knowledge with practical applications, and cover industries with growth potential in Hong Kong and the Asia-Pacific region, ensuring that students can apply what they learn effectively.

THEi’s undergraduate and postgraduate degree programmes are accredited by the Hong Kong Council for Accreditation of Academic and Vocational Qualifications. The curriculum emphasises the practical application of applied science, aligning with the latest developments in business and industry. The undergraduate degree programmes offer 100% work-integrated learning training to support students in building their career paths at an earlier stage.

THEi Chai Wan Campus was awarded the “Leadership in Sustainable Design and Performance Award – Institutional” of the Asia Pacific Leadership in Green Building Awards presented by the World Green Building Council (WorldGBC) in 2020.

Media Contact:

Ms Janice Lam 
Tel: (852) 3890 8227 / (852) 9718 0817
Email: janicelam@thei.edu.hk / media@thei.edu.hk

Ms  Rainbow Chiu 
Tel: (852) 3890 8520
Email: rainbowh@thei.edu.hk  / media@thei.edu.hk

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/when-music-reads-emotion-thei-launches-centre-for-music-therapy-research-to-deepen-guangdong-hong-kong-integration-and-leverage-ai-to-fill-the-healthcare-talent-gap-302885463.html

SOURCE Technological and Higher Education Institute of Hong Kong (THEi)

Continue Reading

Trending